Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Liabilities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Total Liabilities data on record, last reported at $243.5 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 27.25% year-over-year to $243.5 million; the TTM value through Dec 2025 reached $243.5 million, up 27.25%, while the annual FY2025 figure was $243.5 million, 27.25% up from the prior year.
  • Total Liabilities reached $243.5 million in Q4 2025 per ARQT's latest filing, up from -$158.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $280.7 million in Q3 2024 and bottomed at -$224.9 million in Q1 2024.
  • Average Total Liabilities over 5 years is $105.3 million, with a median of $196.4 million recorded in 2024.
  • The widest YoY moves for Total Liabilities: up 891.71% in 2022, down 1161.63% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $110.5 million in 2021, then skyrocketed by 116.97% to $239.7 million in 2022, then increased by 5.43% to $252.7 million in 2023, then dropped by 24.28% to $191.3 million in 2024, then increased by 27.25% to $243.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $243.5 million in Q4 2025, -$158.1 million in Q3 2025, and $213.5 million in Q2 2025.